article thumbnail

Blood pressure trial intervention shows mixed outcomes in chronic kidney disease patients

Medical Xpress - Cardiology

Stanford University School of Medicineled researchers have found that intensive blood pressure (BP) control produces cardiovascular benefits and increases the risk of adverse events in people with chronic kidney disease (CKD).

article thumbnail

Exploring the Interplay Between Chronic Kidney Disease and Cardiovascular Disease

HCPLive

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

article thumbnail

Ozempic Approved for Diabetic Kidney Disease

Med Page Today

(MedPage Today) -- The FDA approved semaglutide (Ozempic) to reduce the risk of kidney disease worsening, kidney failure, and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease (CKD), making it the only.

article thumbnail

Kidney Compass: Semaglutide for Nondiabetic Kidney Disease, with Hiddo Heerspink, PhD, PharmD, at Kidney Week 2024

HCPLive

Hiddo Heerspink, PhD, PharmD, joins the podcast during Kidney Week 2024 to discuss the SMART trial and the potential of semaglutide in people with kidney disease without diabetes.

article thumbnail

FLOW Trial Fortifies Semaglutide's Role in Chronic Kidney Disease and Type 2 Diabetes

HCPLive

mg reduced major kidney disease events and slowed eGFR decline in patients with type 2 diabetes and chronic kidney disease, according to the FLOW trial. Semaglutide 1.0

article thumbnail

Diagnosis of Crohn’s Disease Linked to Chronic Kidney Disease Risk

HCPLive

A diagnosis of chronic kidney disease was approximately 3-times more likely in Crohn's disease than in ulcerative colitis.

article thumbnail

Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial

Cardiovascular Diabetology

Diabetic kidney disease (DKD) is associated with a higher risk of cardiovascular disease (CVD). Pentoxifylline (PTF), a nonselective phosphodiesterase inhibitor with anti-inflammatory, antiproliferative, and a.